You are here:   Content Hub > Pharmavibe > InnoCare Completes IPO on the STAR Market of the Shanghai Stock Exchange in China
Discover your favourite episodes effortlessly
PharmaVibe, capture the dynamics of the pharmaceutical industry
Listen and sense the heartbeat of the industry through news stories, key conferences, and in-depth interviews encompassing an array of specialties, sectors, and areas
Subscribe Now
Access more contents on Content Hub >>
Webniars
Industry Reports
Pharma Sources Insight
EPISODE 23 | 14 MIN | 27 Sep. 2022

InnoCare Completes IPO on the STAR Market of the Shanghai Stock Exchange in China

EPISODE 23 | 14 MIN | 27 Sep. 2022
#Drug Review #R&D #Business #Listing
InnoCare Completes IPO on the STAR Market of the Shanghai Stock Exchange in China
Play
Summary
This week, in China, Nanjing Biosnwill Pharma's Class 2.2 new drug Edaravone Sublingual Tablets and Yichang Humanwell's Class 3 generic drug Clobazam Tablets have been approved by the NMPA for marketing. Meanwhile, new indications have been approved for both Junshi Biosciences' Toripalimab and AstraZeneca's Olaparib Tablets; New progress with the EMA and FDA approvals has been achieved for some popular drugs. For example, Roche's bispecific antibody ophthalmic drug Faricimab has been approved for marketing in the EU. Although there has been nothing new in R&D during the week, on the business side, Chiatai Tianqing entered into a collaboration agreement with Inventiva for the development of lanifibranor, a pan-PPAR agonist. Besides, InnoCare Pharma was successfully listed on the STAR.
Timeline
1
PART1 | 01:20
A new indication for Junshi Biosciences' Toripalimab in combination with standard first-line chemotherapy, was approved for marketing
2
PART2 | 01:46
The new indication for AstraZeneca/ MSD's PARP inhibitor Olaparib Tablets was approved for marketing
3
PART3 | 02:24
Nanjing Biosnwill Pharma's new class 2.2 drug Edaravone Sublingual Tablets was approved for marketing
4
PART4 | 02:51
Yichang Humanwell's Class 3 generic drug Clobazam Tablets was approved for marketing
5
PART5 | 03:20
The marketing application for Orphalan 5.1 class new drug Trientine Hydrochloride Film-coated Tablets was submitted and processed
6
PART6 | 03:46
The marketing application for Pediatrix Therapeutics and Tris Pharma's new class 5.1 drug Methylphenidate Hydrochloride Oral Sustained-release for Suspension was submitted and processed
7
PART7 | 04:23
Otsuka Pharmaceutical's Difamilast Ointment was approved for the clinical treatment of atopic dermatitis in children and adults
8
PART8 | 04:47
Ribo Bio's RBD7022 Injection was approved for clinical treatment of primary hypercholesterolemia or mixed hyperlipidemia featuring elevated LDL cholesterol
9
PART9 | 05:16
Innovent's IBI333 was approved for clinical treatment of neovascular and age-related macular degeneration
10
PART10 | 05:45
Ori-C101 Injection from Oricell Therapeutics was approved for clinical treatment of advanced hepatocellular carcinoma
11
PART11 | 06:13
The clinical trial application for BRL-201 submitted by BRL Medicine was accepted
12
PART12 | 06:43
Lepu Biopharma's MRG003 for injection is proposed to be included in the breakthrough therapy designation
13
PART13 | 07:20
A new indication of Eli Lilly's Selpercatinib for the treatment of patients with locally advanced or metastatic solid tumors with RET gene fusions was approved by the FDA
14
PART14 | 07:50
Cidara and Melinta Therapeutics jointly announced that the FDA has processed a marketing application for Rezafungin
15
PART15 | 08:19
Argenx announced that the FDA has processed a Biologics License Application for subcutaneous injection of Efgartigimod for the treatment of adult patients with generalized myasthenia gravis
16
PART16 | 08:49
Antengene Corporation's self-developed novel PD-L1/4-1BB bispecific antibody ATG-101 injection was granted orphan drug designation by the FDA
17
PART17 | 09:37
Roche announced that Faricimab was approved for marketing by the EMA for the treatment of nAMD and visual impairment due to DME
18
PART18 | 10:00
AstraZeneca's Tezepelumab was approved by the EMA for marketing as an additional maintenance treatment for patients aged 12 years and above with severe asthma
19
PART19 | 10:35
EMA accepted two marketing authorization applications of UCB'S Bimekizumab for the treatment of adults with PsA and axSpA
20
PART20 | 11:00
Merck to Initiate new phase 3 clinical program with lower dose of daily oral Islatravir in combination with doravirine for treatment of people with HIV-1 infection
21
PART21 | 11:31
Fosun Pharmaceutical started an international multicenter phase II clinical trial of SurVaxM in combination with temozolomide for adjuvant treatment of glioblastoma in primary diagnosis
22
PART22 | 12:01
Pfizer unveiled the latest study data for PF-06882961 and PF-07081532 which showed significant results for glucose-lowering and weight loss compared to placebo
23
PART23 | 12:28
RemeGen Announces Preliminary Results of Phase III Confirmatory Study of Telitacicept for Treatment of Systemic Lupus Erythematosus in China
24
PART24 | 12:57
Inventiva and Sino Biopharm announce licensing and collaboration agreement to develop and commercialize lanifibranor in Greater China
25
PART25 | 13:28
InnoCare Completes Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
You can listen and/or download the episode on Podbean, or directly through iTunes, GooglePlay, Amazon Music and Samsung Podcasts. You can also subscribe our podcast by RSS feed, please copy the full URL below.
RSS Feed:
https://feed.podbean.com/PharmaSources/feed.xml
Copy Feed
Full Transcript

Drug Review

 

NMPA – Marketing

[Approval]

1. On September 19, the NMPA's official website released the approval that, a new indication for Junshi Biosciences' PD-1 monoclonal antibody, Toripalimab, in combination with standard first-line chemotherapy has been approved for marketing for the treatment of untreated, driver gene (EGFR/ALK)-negative and advanced NSCLC. This is the sixth indication for which Toripalimab has been approved in China.

 

2. On September 19, the NMPA's official website released the approval that, the new indication for AstraZeneca/ MSD's PARP inhibitor Olaparib Tablets has been approved for marketing. It is used for the maintenance treatment of adult patients with homologous recombination deficiency (HRD)-positive and advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer after complete response or partial response with first-line platinum-containing chemotherapy in combination with bevacizumab. This is the fourth indication for which Olaparib Tablets have been approved in China.

 

3. On September 19, NMPA's official website released the approval that Nanjing Biosnwill Pharma's new class 2.2 drug Edaravone Sublingual Tablets has been approved for marketing, with an indication of inhibiting the progression of dysfunction caused by amyotrophic lateral sclerosis (ALS). Thus, Nanjing Biosnwill Pharma emerged as the first pharmaceutical company to obtain marketing approval for Edaravone Sublingual Tablets.

 

4. On September 19, the NMPA official website released the approval that Yichang Humanwell's Class 3 generic drug Clobazam Tablets has been approved for marketing for the treatment of intractable epilepsy known as Lennox-Gastaut syndrome (LGS). Clobazam is a new class of 1,5-benzodiazepine antiepileptic drugs with proven efficacy against epilepsy in pediatric and adult LGS patients aged 2 years old and above.


 

NMPA – Marketing

[Application]

5. On September 21, the CDE official website revealed that the marketing application for Orphalan 5.1 class new drug Trientine Hydrochloride Film-coated Tablets has been submitted and processed. Trientine is a copper ion complexing agent that has previously been approved overseas for the treatment of Wilson's disease (hepatolenticular degeneration). It is a rare chronic genetic disease that has been included in the First Catalogue of Rare Diseases in China.

 

6. On September 21, the CDE official website revealed that the marketing application for the new class 5.1 drug Methylphenidate Hydrochloride Oral Sustained-release for Suspension jointly developed by Pediatrix Therapeutics and Tris Pharma has been submitted and processed. Methylphenidate hydrochloride is a central nervous system (CNS) stimulant for the treatment of attention deficit hyperactivity disorder (ADHD) and can act within 45 minutes.


 

NMPA – Clinical Trials

[Approval]

7. On September 19, the CDE official website revealed that Otsuka Pharmaceutical's Difamilast Ointment has been approved for the clinical treatment of atopic dermatitis in children and adults. Difamilast is a nonsteroidal topical phosphodiesterase-4 (PDE4) inhibitor that exerts its anti-inflammatory effects by blocking the production of cytokines and chemical mediators.

 

8. On September 19, the CDE official website revealed that Ribo Bio's RBD7022 Injection has been approved for clinical treatment of primary (familial and non-familial) hypercholesterolemia or mixed hyperlipidemia featuring elevated LDL cholesterol. This is the first siRNA therapy for ASGPR and PCSK9 developed independently by a Chinese pharmaceutical company to be approved for clinical use.

 

9. On September 20, the CDE official website revealed that Innovent's IBI333 has been approved for clinical treatment of neovascular and age-related macular degeneration. IBI333 is a fully human fusion protein bispecific antibody that targets both VEGF-A and VEGF-C. In a laser-induced choroidal neovascularization model, IBI333 can inhibit free VEGF-A and VEGF-C.

 

10. On September 21, the CDE official website revealed that Ori-C101 Injection from Oricell Therapeutics has been approved for clinical treatment of advanced hepatocellular carcinoma. Ori-C101 Injection is a fully human antibody sequence targeting GPC3 with high specificity and affinity, and a unique signaling activation element, Ori, which is intended for the treatment of adult patients with advanced hepatocellular carcinoma.

 


[Application]

11. On September 19, the CDE official website revealed that the clinical trial application for BRL-201 submitted by BRL Medicine has been accepted. BRL-201 is the world's first CAR-T product targeting CD19 non-viral PD1 sentinel integration, which can obtain genomic sentinel integration CAR-T cell product by one-step preparation without the use of viral vectors.

 


[Breakthrough Therapy]

12. On September 21, the CDE official website revealed that Lepu Biopharma's MRG003 for injection is proposed to be included in the breakthrough therapy designation for the treatment of recurrent/metastatic nasopharyngeal carcinoma that has failed previous treatment with at least second-line systemic chemotherapy (including platinum-containing chemotherapy) and PD-1 (L1). MRG003 is an ADC drug targeting EGFR on the surface of tumor cells, delivering precisely cytotoxic small molecules to tumor cells via the antibody portion.

 

 

FDA - Marketing

[Approval]

13. On September 21, Eli Lilly announced accelerated FDA approval for a new indication of Selpercatinib (Retevmo) for the treatment of patients with locally advanced or metastatic solid tumors with rearranged during transfection (RET) gene fusions. These patients had suffered disease progression after prior systemic therapy or had no other satisfactory alternative treatment. This is the first and only cancer-independent RET inhibitor for the treatment of solid tumors with RET gene fusions in the world.

 


[Application]

14. On September 20, Cidara and Melinta Therapeutics jointly announced that the FDA has processed a marketing application for Rezafungin for the treatment of candidemia and invasive candidiasis (IC) and granted it priority review status with a PDUFA date of March 22, 2023. IC is a serious and life-threatening systemic candidiasis that can infect the bloodstream, and deep/invasive tissues.

 

15. On September 22, Argenx announced that the FDA has processed a Biologics License Application (BLA) for subcutaneous injection of Efgartigimod for the treatment of adult patients with generalized myasthenia gravis. Efgartigimod is a "first-in-class" therapy targeting the Fc receptor, which has been approved for marketing by the FDA in December 2021. Zai Lab has the right to develop and commercialize it in Greater China.

 


[Orphan Drug Designation]

16. On September 19, Antengene Corporation announced that its self-developed novel PD-L1/4-1BB bispecific antibody ATG-101 injection has been granted orphan drug designation by the FDA for the treatment of pancreatic cancer. At present, there is no PD-L1/4-1BB bispecific antibody approved for the treatment of pancreatic cancer worldwide. In December 2021, as the first new bispecific antibody drug of Antengene Corporation, the clinical trial application of ATG-101 injection has been processed by the NMPA for the treatment of solid tumors and non-Hodgkin's lymphoma.


 

EMA – Marketing

[Approval]

17. On September 19, Roche announced that Faricimab (Vabysmo) has been approved for marketing by the EMA for the treatment of neovascular or ‘wet’ age-related macular degeneration (nAMD) and visual impairment due to diabetic macular edema (DME). Faricimab is the first VEGF-A/ANG-2 bispecific antibody developed for ophthalmic disease and is the only injectable ophthalmic drug approved in Europe.

 

18. On September 21, AstraZeneca announced that Tezepelumab (Tezspire) has been approved by the EMA for marketing as an additional maintenance treatment for patients aged 12 years and above with severe asthma. This is the first and only biologic approved by EMA that is not restricted by any phenotype or biomarker for the treatment of patients with severe asthma. Tezspire, a monoclonal antibody targeting TSLP, was co-developed by AstraZeneca and Amgen and has been approved for marketing in the U.S. and other countries.


 

[Application]

19. On September 20, UCB announced that EMA has accepted two marketing authorization applications (MAAs) of Bimekizumab for the treatment of adults with active psoriatic arthritis (PsA) and active axial spondyloarthritis (axSpA). This is the only monoclonal antibody against IL-17A/IL-17F approved for marketing in the world.

 

 

 

R&D

 

Clinical trials launching

20. On September 20, MSD announced that it will initiate a new Phase III clinical trial with once-daily oral Islatravir for the treatment of people with HIV-1 infection, evaluating a once-daily oral combination of doravirine (100 mg) in combination with a lower dose of Islatravir (0.75 mg) (DOR/ISL). The FDA has reviewed and approved the plan. Islatravir is a nucleoside reverse transcriptase translocation inhibitor (NRTTI) in development that inhibits the function of HIV reverse transcriptase through multiple mechanisms.

 

21. On September 21, the drug clinical trial registration and information publicity platform of CDE showed that Fosun Pharmaceutical has started an international multicenter (including China) phase II clinical trial of SurVaxM in combination with temozolomide for adjuvant treatment of glioblastoma in primary diagnosis. SurVaxM is a peptide vaccine developed by MimiVax. Fosun Pharma acquired its exclusive clinical development and commercialization rights in China in 2019.

 


Clinical data release

22. On September 21, Pfizer unveiled the latest study data for PF-06882961 (2 oral doses per day) and PF-07081532 (1 oral dose per day), which showed significant results for glucose-lowering and weight loss compared to placebo. The two are oral small molecule GLP-1 receptor agonists. Currently, Semaglutide Tablets is the only oral GLP-1R agonist marketed in the world.

 

23. On September 19, Remegen announced that the Phase III confirmatory study of its Telitacicept (Taiai) for treatment of systemic lupus erythematosus (SLE) has been completed and preliminary results were obtained in China. The study met the prespecified clinical endpoints, with a significantly higher rate of SRI-4 (The Systemic Lupus Erythematosus Responder Index 4) response in the Telitacicept group (82.6%) compared to the placebo group (38.1%) at week 52.

 


 

Business

 

24. On September 21, Inventiva announced that it entered into a collaboration agreement with Chiatai Tianqing to jointly develop and commercialize Lanifibranor, a pan-PPAR agonist developed in-house by Inventiva, for the treatment of nonalcoholic steatohepatitis (NASH) and other potential metabolic diseases. Under the terms of the agreement, Inventiva has the potential to receive up to $290 million of clinical, regulatory, and commercial milestone payments.

 

 


Listing

 

STAR Market

25. On September 21, InnoCare Pharma got officially listed on the Science and Technology Innovation Board (STAR market) of the Shanghai Stock Exchange. There are two products of InnoCare Pharma approved for marketing, the BTK inhibitor Orelabrutinib and the anti-CD19 antibody Tafasitamab. More than 30 clinical trials are underway worldwide for 13 products of the Company.

Read More
The First Domestically Developed JAK Inhibitor Ivarmacitinib is Expected to Be First Marketed in China for Autoimmune System Diseases
EPISODE 30 |  16 MIN  |  22 Nov. 2022
#Drug Review #R&D #Business
The online platform for CPHI & PMEC China is fully live now! The online event will be live for 54 days to help you connect for an extended period of time. Looking back on this week's pharma news, BeiGene's new indication for Zanubrutinib was approved in the EU while TopAlliance submitted a marketing application for the anti-PD-1 monoclonal antibody Toripalimab in the EU. The most noteworthy in the R&D section is Hengrui's JAK inhibitor Phase III clinical success, making it be expected to become the first product made in China in the field of autoimmune system diseases.
Play
NMPA Nod Gives YL-Pharma First Highly Selective PI3Kδ Inhibitor Marketing Approval in China
EPISODE 29 |  14 MIN  |  15 Nov. 2022
#Drug Review #R&D #Business
This week, the first highly selective PI3Kδ inhibitor in China, linperlisib of YL-Pharma, was approved for marketing. Multiple positive results have been released from several clinical trials, but GSK announced that the Phase III superiority trial of its BCMA ADC combined with pomalidomide in the treatment of relapsed or refractory multiple myeloma, did not meet its primary endpoint of progression-free survival (PFS). Jumpcan Pharmaceutical entered into a cooperation agreement with Newsoara and obtained the development rights of two innovative drugs.
Play
The Marketing Approval of Luye Pharma’s First-in-class Anti-depressant Drug in China
EPISODE 28 |  14 MIN  |  08 Nov. 2022
#Drug Review #R&D #Business
This week, Toludesvenlafaxine Hydrochloride Extended-Release Tablets, a kind of first-in-class anti-depressant drug developed by the Chinese company Luye Pharma, was approved for marketing. In terms of R&D, the phase III clinical research of PCSK9 Monoclonal Antibody developed by Akeso met the endpoints and was planned to apply for marketing. In terms of business, SonnetBio and Janssen, a subsidiary of Johnson & Johnson, reached a cooperation agreement on three candidate products.
Play
The Marketing Declaration of HAISCO's Novel Analgesic for Diabetic Peripheral Neuralgia Treatment
EPISODE 27 |  13 MIN  |  01 Nov. 2022
#Drug Review #R&D #Business #Listing #COVID-19
The marketing application of HAISCO's first-in-class HSK16149 Capsule was submitted, presumably for the treatment of diabetic peripheral neuralgia. While in the global markets, Simcere Pharmaceutical's SIM0237 had been approved for clinical use in the United States for the treatment of locally advanced unresectable or metastatic solid tumors. In terms of R&D, several clinical trials achieved positive results, while Alpine Immune terminated two clinical trials of davoceticept due to the death of patients.
Play
Subscribe Now